Tabel 2 nedenfor viser hyppigheden af alle bivirkninger, der forekom i > 10% af perioderne i hver behandlingsgruppe i fase 1- 4- forsøg hos patienter med lymfomatøs meningitis, som modtog DepoCyte eller cytarabin:
The incidence of all adverse reactions occurring in > 10% of cycles in either treatment group in Phase 1-4 studies in patients with lymphomatous meningitis receiving DepoCyte or cytarabine is given in Table 2 below: